Literature DB >> 34124899

Dynamic Profiling of β-Coronavirus 3CL Mpro Protease Ligand-Binding Sites.

Eunice Cho1, Margarida Rosa1, Ruhi Anjum2, Saman Mehmood3, Mariya Soban2, Moniza Mujtaba4, Khair Bux5, Syed T Moin5, Mohammad Tanweer1, Sarath Dantu6, Alessandro Pandini6, Junqi Yin7, Heng Ma8, Arvind Ramanathan8,9, Barira Islam10, Antonia S J S Mey11, Debsindhu Bhowmik12, Shozeb Haider1.   

Abstract

β-coronavirus (CoVs) alone has been responsible for three major global outbreaks in the 21st century. The current crisis has led to an urgent requirement to develop therapeutics. Even though a number of vaccines are available, alternative strategies targeting essential viral components are required as a backup against the emergence of lethal viral variants. One such target is the main protease (Mpro) that plays an indispensable role in viral replication. The availability of over 270 Mpro X-ray structures in complex with inhibitors provides unique insights into ligand-protein interactions. Herein, we provide a comprehensive comparison of all nonredundant ligand-binding sites available for SARS-CoV2, SARS-CoV, and MERS-CoV Mpro. Extensive adaptive sampling has been used to investigate structural conservation of ligand-binding sites using Markov state models (MSMs) and compare conformational dynamics employing convolutional variational auto-encoder-based deep learning. Our results indicate that not all ligand-binding sites are dynamically conserved despite high sequence and structural conservation across β-CoV homologs. This highlights the complexity in targeting all three Mpro enzymes with a single pan inhibitor.

Entities:  

Year:  2021        PMID: 34124899     DOI: 10.1021/acs.jcim.1c00449

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  8 in total

1.  The Role of Hydrophobic Nodes in the Dynamics of Class A β-Lactamases.

Authors:  Edgar Olehnovics; Junqi Yin; Adrià Pérez; Gianni De Fabritiis; Robert A Bonomo; Debsindhu Bhowmik; Shozeb Haider
Journal:  Front Microbiol       Date:  2021-09-21       Impact factor: 5.640

2.  Conserved coronavirus proteins as targets of broad-spectrum antivirals.

Authors:  Cleber C Melo-Filho; Tesia Bobrowski; Holli-Joi Martin; Zoe Sessions; Konstantin I Popov; Nathaniel J Moorman; Ralph S Baric; Eugene N Muratov; Alexander Tropsha
Journal:  Antiviral Res       Date:  2022-06-09       Impact factor: 10.103

3.  Machine learning prediction of 3CLpro SARS-CoV-2 docking scores.

Authors:  Lukas Bucinsky; Dušan Bortňák; Marián Gall; Ján Matúška; Viktor Milata; Michal Pitoňák; Marek Štekláč; Daniel Végh; Dávid Zajaček
Journal:  Comput Biol Chem       Date:  2022-02-26       Impact factor: 3.737

4.  Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease.

Authors:  Shunzhou Wan; Agastya P Bhati; Alexander D Wade; Dario Alfè; Peter V Coveney
Journal:  Mol Syst Des Eng       Date:  2021-11-18

5.  Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals.

Authors:  Yin-Sui Xu; Jia-Zhu Chigan; Jia-Qi Li; Huan-Huan Ding; Le-Yun Sun; Lu Liu; Zhenxin Hu; Ke-Wu Yang
Journal:  Bioorg Chem       Date:  2022-04-18       Impact factor: 5.307

6.  Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms.

Authors:  Julia M Flynn; Neha Samant; Gily Schneider-Nachum; David T Barkan; Nese Kurt Yilmaz; Celia A Schiffer; Stephanie A Moquin; Dustin Dovala; Daniel N A Bolon
Journal:  Elife       Date:  2022-06-20       Impact factor: 8.713

7.  Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid.

Authors:  Jonathan T Lee; Qingyi Yang; Alexey Gribenko; B Scott Perrin; Yuao Zhu; Rhonda Cardin; Paul A Liberator; Annaliesa S Anderson; Li Hao
Journal:  mBio       Date:  2022-07-13       Impact factor: 7.786

8.  Developing evolution-resistant drugs for COVID-19.

Authors:  Daniel M Weinreich
Journal:  Elife       Date:  2022-07-26       Impact factor: 8.713

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.